Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis

Bone Marrow Transplantation

Volumn 46, Issue 4, 2011, Pages 557-561

  Lissandre, S ^a   Bay, J O ^b   Cahn, J Y ^c   Porcher, R ^a   Cacheux, V ^b   Cabrespine, A ^b   Cornillon, J ^d   Cassinat, B ^a   Peffault De Latour, R ^a   Socie, G ^a   Robin, M ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b HÔTEL DIEU   (France)

^c HÔPITAL MICHALLON   (France)

^d Institut de Cancerologie de la Loire   (France)

Author keywords

allogeneic haematopoietic stem cell transplantation; CMV; GvHD; JAK2 V617F mutation; myelofibrosis

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HYPERSPLENISM; IMMUNOSUPPRESSIVE TREATMENT; MALE; MALIGNANT TRANSFORMATION; MONOTHERAPY; MORTALITY; MYELOFIBROSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RADIOTHERAPY; REDUCED INTENSITY CONDITIONING; RELAPSE FREE SURVIVAL; RETROSPECTIVE STUDY; SPLENECTOMY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MIDDLE AGED; PRIMARY MYELOFIBROSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 79953717394     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.276     Document Type: Article

References (21)

1. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol 1999; 61: 10-15. (Pubitemid 29218171)
2. Cervantes F, Villamor N, Esteve J, Montoto S, Rives S, Rozman C et al. 'Lymphoid' blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features. Br J Haematol 1998; 100: 123-128. (Pubitemid 28051849)
3. Okamura T, Kinukawa N, Niho Y, Mizoguchi H. Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol 2001; 73: 194-198. (Pubitemid 33758860)
4. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013-1018. (Pubitemid 26333326)
5. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895-2901.
6. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005; 105: 973-977. (Pubitemid 40170863)
7. Guardiola P, Anderson JE, Bandini G, Cervantes F, Runde V, Arcese W et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999; 93: 2831-2838. (Pubitemid 29200773)
8. Kerbauy DM, Gooley TA, Sale GE, Flowers ME, Doney KC, Georges GE et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced poly-cythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 2007; 13: 355-365.
9. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112: 3065-3072.
10. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
11. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217. (Pubitemid 10036817)
12. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
13. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
14. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919. (Pubitemid 41510773)
15. Prentice RL, Kalbfleisch JD, Peterson Jr AV, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics 1978; 34: 541-554. (Pubitemid 9067879)
16. Barosi G, Ambrosetti A, Centra A, Falcone A, Finelli C, Foa P et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood 1998; 91: 3630-3636. (Pubitemid 28225729)
17. Kroger N, Holler E, Kobbe G, Bornhauser M, Schwerdtfeger R, Baurmann H et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 5264-5270.
18. Patriarca F, Bacigalupo A, Sperotto A, Isola M, Soldano F, Bruno B et al. Allogeneic hematopoietic stem cell transplanta-tion in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haemato-logica 2008; 93: 1514-1522.
19. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neo-plasms Research and Treatment). Blood 2010; 115: 1703-1708.
20. Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C et al. Allogeneic hematopoietic stem cell transplan-tation for myelofibrosis. Blood 2003; 102: 3912-3918. (Pubitemid 37486970)
21. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cyto-megalovirus (CMV)-seronegative recipients of stem cell trans-plants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185: 273-282. (Pubitemid 34107239)